ASP Calculation Rankles IG; Drugs To Face Dropping Reimbursement Rates?
Executive Summary
The HHS Office of Inspector General is dissatisfied with the CMS' response to an OIG report showing that comparison of a Part B-reimbursed drug's average sales price (ASP) with its average manufacturer price (AMP) yields different results based on the calculation method used
You may also be interested in...
WAMP-Based Part B Reimbursement For Five Drugs Could Save $67 Mil. – OIG
The HHS Office of Inspector General (OIG) contends that reimbursement for five Medicare Part B drugs is too high relative to their market prices and recommends that CMS lower payment levels for them
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011